European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in …
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the …
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. …
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped …
The Biogen headquarters in Cambridge, Massachusetts, on Tuesday, Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of …
As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason …
Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient …
Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson …
Here are the most important news items that investors need to start their trading day: 1. Dow on a tear 2. Bank earnings drive the day 3. Goldman drops recession …
The Food and Drug Administration (FDA) fully approved the Alzheimer’s treatment Leqembi on Thursday, marking a significant expansion in access to the costly drug for older Americans. Medicare announced that …